ArticleFrontiers in pharmacology2019
Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 58 citations in OpenAlex.
- Mendelian Randomization Analysis of Psoriasis and Multiparameter Renal Function Trajectories.Endocrine, metabolic & immune disorders drug targets · 2026Article
- The SGK1/ENaC axis in renal injury during salt-sensitive hypertension: from sodium sensing to inflammation.Frontiers in immunology · 2026Review
- CD4Frontiers in immunology · 2026Review
- Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease.Kidney360 · 2025Review
- Beyond Blood Pressure: Emerging Pathways and Precision Approaches in Hypertension-Induced Kidney Damage.International journal of molecular sciences · 2025Review
- Aryl Hydrocarbon Receptor Activation Promotes Effector CD4+ T Cell Homeostasis and Restrains Salt-Sensitive Hypertension.Function (Oxford, England) · 2025Article
- Imbalance of T cell subsets: a core event that mediates the progression of T2DM and its complications.Frontiers in immunology · 2025Review
- Review of mechanisms and frontier applications in IL-17A-induced hypertension.Open medicine (Warsaw, Poland) · 2025Review
- Blood indices of inflammation and their association with hypertension in smokers: analysis using data mining approaches.Journal of human hypertension · 2025Article
- Exosome-mediated renal protection: Halting the progression of fibrosis.Genes & diseases · 2024Review
- Immune mechanisms in the pathophysiology of hypertension.Nature reviews. Nephrology · 2024Review
- IL-6 and IL-17 as potential links between pre-existing hypertension and long-term COVID sequelae in patients undergoing hemodialysis: a multicenter cross-sectional study.Scientific reports · 2024Article
- Chronic Kidney Disease and Periodontitis Interplay-A Narrative Review.International journal of environmental research and public health · 2023Review
- T cells and their products in diabetic kidney disease.Frontiers in immunology · 2023Review
- Exploring the role of T helper subgroups and their cytokines in the development of pregnancy-induced hypertension.Frontiers in immunology · 2023Article
- Responses Triggered by the Immune System in Hypertensive Conditions and Repercussions on Target Organ Damage: A Review.Current cardiology reviews · 2023Review
- Deeper insight into the role of IL-17 in the relationship beween hypertension and intestinal physiology.Journal of inflammation (London, England) · 2022Review
- Lysophosphatidic Acid Is a Proinflammatory Stimulus of Renal Tubular Epithelial Cells.International journal of molecular sciences · 2022Article
- Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice.Pflugers Archiv : European journal of physiology · 2022Article
- [Interleukin-17A is closely correlated with the progression of renal epithelial-mesenchymal transition in spontaneously hypertensive rats].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is now considered as an inflammatory disease, and the kidney is a key end-organ target. Experimental and clinical studies suggest that interleukin 17A (IL-17A) is a promising therapeutic target in immune and chronic inflammatory diseases, including hypertension and kidney disease. Elevated circulating IL-17A levels have been observed in hypertensive patients. Our aim was to investigate whether chronically elevated circulating IL-17A levels could contribute to kidney damage, using a murine model of systemic IL-17A administration. Blood pressure increased after 14 days of IL-17A infusion in mice when compared with that in control mice, and this was associated to kidney infiltration by inflammatory cells, including CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.